Critical Therapeutics, Inc. to Announce Third Quarter Financial Results on November 3, 2004.LEXINGTON, Mass. -- Critical Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , Inc. (Nasdaq: CRTX), a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases, will conduct a conference call at 5:00 p.m. ET Wednesday, November 3, 2004, following the release of its third quarter 2004 financial results. Critical Therapeutics President and Chief Executive Officer Paul Rubin, M.D. will lead the call, during which senior management will discuss the Company's third quarter financial results, recent accomplishments and upcoming milestones. Investors and others are invited to listen live via telephone or the Internet Internet Publicly accessible computer network connecting many smaller networks from around the world. It grew out of a U.S. Defense Department program called ARPANET (Advanced Research Projects Agency Network), established in 1969 with connections between computers at the .
What: Critical Therapeutics' Third Quarter 2004 Financial Results
Conference Call
When: 5:00 p.m. ET Wednesday, November 3, 2004
Dial-in: From the U.S. and Canada, dial (800) 479-9001
International callers, dial (719) 457-2618
Webcast: Visit www.criticaltherapeutics.com, go to the "Investors"
page and then click on the conference call link about five
minutes before the call.
A replay of the conference call will be available from approximately 8:00 p.m. ET November 3, 2004 until midnight ET November 9, 2004. To hear the replay, dial (888) 203-1112 from the U.S. and Canada and (719) 457-0820 from other locations. The replay passcode is 883653. To access the replay via webcast, visit www.criticaltherapeutics.com, click on "Investors" and then on "Webcasts & Presentations." About Critical Therapeutics, Inc. Critical Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The Company is developing a sales and marketing infrastructure in connection with its in-licensed product, Zyflo Zileuton (Zyflo) A medication that interferes with the biosynthetic pathway that produces leukotrienes; used to help prevent asthma attacks. Mentioned in: Leukotriene Inhibitors Zyflo® Zileuton, see there (R), a tablet See digitizer tablet and tablet computer. TABLET - A query language. ["Human Factor Comparison of a Procedural and a Non-procedural Query Language", C. Welty et al, ACM Trans Database Sys 6(4):626-649 (Dec 1981)]. formulation formulation /for·mu·la·tion/ (for?mu-la´shun) the act or product of formulating. American Law Institute Formulation of zileuton zileuton /zi·leu·ton/ (zi-loo´ton) an inhibitor of leukotriene formation, used as an antiasthmatic. Zileuton (Zyflo) . Critical Therapeutics is also developing treatments directed toward the severe inflammatory response in acute diseases and conditions that lead to admission to the emergency room or intensive care unit, and acute exacerbations of other chronic diseases that frequently lead to hospitalization hospitalization /hos·pi·tal·iza·tion/ (hos?pi-t'l-i-za´shun) 1. the placing of a patient in a hospital for treatment. 2. the term of confinement in a hospital. . For more information, please visit www.criticaltherapeutics.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion